Treatment of heroin (diamorphine) addiction - Current approaches and future prospects

被引:39
作者
Gonzalez, G [1 ]
Oliveto, A [1 ]
Kosten, TR [1 ]
机构
[1] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, Dept Psychiat,Div Subst Abuse 116A4, West Haven, CT 06516 USA
关键词
D O I
10.2165/00003495-200262090-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
New pharmacological treatments for heroin (diamorphine) addiction include drugs that reduce opiate withdrawal symptoms and agents that are given during the maintenance phase of treatment. A variety of different types of pharmacological agents (opioid agonists, partial opioid agonists, opioid antagonists and alpha(2)-adrenoreceptor agonists) are reviewed and the evidence of their use during managed withdrawal and maintenance are presented. Experimental approaches attempting to reduce the time of opiate withdrawal and to accelerate the transition to abstinence are being developed. The combination tablet of buprenorphine and naloxone that is to be introduced for office-based maintenance is currently undergoing intense evaluation in the US. This new approach may facilitate the expansion of treatment while reducing the potential for medication diversion and intravenous use. The use of heroin continues to increase and is estimated that eight million people in the world (0.14%) abuse opiates. The regions with the highest annual prevalence (2%) are South East and South West Asia,([1]) and based on the National Household Survey.([2]) the annual prevalence of heroin use in the US is 0.3% with a rising trend of heroin use in the last 2 years.[3] Comprehensive treatments for heroin dependence include environmental changes. psychosocial interventions and pharmacotherapy. Recent advances in pharmacotherapy are aimed at reducing problems associated with persistent heroin use and expanding the accessibility of long-term treatment. For example, the introduction of the combination tablet of buprenorphine and naloxone into drug abuse treatment in an office-based setting should expand available treatment slots and facilitate general medical care of individuals who are addicted.([4,5]) This review focuses on the rationale, indications and limitations of medications that either facilitate the reduction of withdrawal symptoms during detoxification or improve the overall psychosocial stabilisation during maintenance, and briefly discusses potential future directions for opiate dependence treatments.
引用
收藏
页码:1331 / 1343
页数:13
相关论文
共 103 条
[51]   Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine [J].
Kuhlman, JJ ;
Levine, B ;
Johnson, RE ;
Fudala, PJ ;
Cone, EJ .
ADDICTION, 1998, 93 (04) :549-559
[52]   SAFETY AND SIDE-EFFECTS OF BUPRENORPHINE IN THE CLINICAL MANAGEMENT OF HEROIN-ADDICTION [J].
LANGE, WR ;
FUDALA, PJ ;
DAX, EM ;
JOHNSON, RE .
DRUG AND ALCOHOL DEPENDENCE, 1990, 26 (01) :19-28
[53]   2 CASES OF CLONIDINE ABUSE DEPENDENCE IN METHADONE-MAINTAINED PATIENTS [J].
LAUZON, P .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 1992, 9 (02) :125-127
[54]   Ultra rapid opiate detoxification as compared to 30-day inpatient detoxification program - A retrospective follow-up study [J].
Lawental, E .
JOURNAL OF SUBSTANCE ABUSE, 2000, 11 (02) :173-181
[55]  
LERNER A, 1992, ISRAEL J PSYCHIAT, V29, P36
[56]   Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal [J].
Lin, SK ;
Strang, J ;
Su, LW ;
Tsai, CJ ;
Hu, WH .
DRUG AND ALCOHOL DEPENDENCE, 1997, 48 (02) :127-133
[57]   Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial [J].
Ling, W ;
Charuvastra, C ;
Collins, JF ;
Batki, S ;
Brown, LS ;
Kintaudi, P ;
Wesson, DR ;
McNicholas, L ;
Tusel, DJ ;
Malkerneker, U ;
Renner, JA ;
Santos, E ;
Casadonte, P ;
Fye, C ;
Stine, S ;
Wang, RIH ;
Segal, D .
ADDICTION, 1998, 93 (04) :475-486
[58]  
LING W, 1976, ARCH GEN PSYCHIAT, V33, P709
[59]   NALOXONE TREATMENT FOR OPIATE WITHDRAWAL SYNDROME [J].
LOIMER, N ;
SCHMID, R ;
PRESSLICH, O ;
LENZ, K .
BRITISH JOURNAL OF PSYCHIATRY, 1988, 153 :851-852
[60]   ACUTE BLOCKING OF NALOXONE-PRECIPITATED OPIATE WITHDRAWAL SYMPTOMS BY METHOHEXITONE [J].
LOIMER, N ;
SCHMID, R ;
LENZ, K ;
PRESSLICH, O ;
GRUNBERGER, J .
BRITISH JOURNAL OF PSYCHIATRY, 1990, 157 :748-752